Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors

Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive combination therapy, the median life expectancy for patients with GBM remains approximately 14 months. In order to improve the outcomes of patients with GBM, the development of newer treatments is critical. T...

Full description

Saved in:
Bibliographic Details
Published in:Brain tumor research and treatment 2013, 1(1), , pp.2-8
Main Authors: Nicholas, Sarah, Mathios, Dimitris, Ruzevick, Jacob, Jackson, Christopher, Yang, Isaac, Lim, Michael
Format: Article
Language:English
Subjects:
Review
신경외과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive combination therapy, the median life expectancy for patients with GBM remains approximately 14 months. In order to improve the outcomes of patients with GBM, the development of newer treatments is critical. The concept of using the immune system as a therapeutic option has been suggested for several decades; by harnessing the body's adaptive immune mechanisms, immunotherapy could provide a durable and targeted treatment against cancer. However, many cancers, including GBM, have developed mechanisms that protect tumor cells from being recognized and eliminated by the immune system. For new immunotherapeutic regimens to be successful, overcoming immunosuppression via immune checkpoint signaling should be taken into consideration.
ISSN:2288-2405
2288-2413
DOI:10.14791/btrt.2013.1.1.2